Skip to main content
. 2017 Jul 6;117(4):583–587. doi: 10.1038/bjc.2017.210

Table 1. Characteristics of tumours and patients with TUBR.

  TERT promoter mutation
Variables n Mutated (n=280) Wild type (n=68) P-valuea
Age at diagnosis (years)
Median (range) 348 74 (34–97) 68 (27–95) 0.0017
Sex
Female 52 39 (75.0%) 13 (25.0%) 0.2816
Male 296 241 (81.4%) 55 (18.6%)  
Tumour stage
pTa 199 158 (79.4%) 41 (21.6%) 0.4979
pT1 76 59 (77.6%) 17 (22.4%)  
>pT1 61 52 (85.2%) 9 (14.8%)  
pTis concomitant 12 11 (91.7%) 1 (8.3%)  
Histological grade
Low-grade 144 107 (74.3%) 37 (25.7%) 0.0150
High-grade 204 173 (84.8%) 31 (15.2%)  
Cytology
Negative 115 84 (73.0%) 31 (27.0%) 0.1103
AUC-USb 19 17 (89.5%) 2 (10.5%)  
Low-grade 97 79 (81.4%) 18 (18.6%)  
AUC-Hb 8 6 (75.0%) 2 (25.0%)  
High-grade 109 94 (86.2%) 15 (13.8%)  

Abbreviations: AUC-H=Atypical urothelial cells of high grade; AUC-US=atypical urothelial cells of undetermined significance; TERT=telomerase reverse transcriptase.

a

P-values correspond to χ2-test or Mann-Whitney test (age).

b

Atypical urothelial cells of undetermined significance (AUC-US) or cannot exclude high grade (AUC-H).